



Lumos Pharma to Participate in Upcoming Investor Conferences

May 16, 2022

AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- [Lumos Pharma, Inc.](#) (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the following upcoming investors conferences:

Event: **H.C. Wainwright 2022 Global Investment Conference – May 23rd – 26th**
Presentation: Live presentation May 25th at 4:00 – 4:30 PM EDT
Webcast link: [Here](#)

Event: **Jefferies Healthcare Conference – June 8th – 10th**
Presentation: Live fireside chat June 8th at 3:30 – 3:55 PM EDT
Webcast link: [Here](#)

The webcasts for each presentation can also be found on the Company's website under "[Events & Presentations](#)" in the Investors & Media section where a replay of each presentation will be also be available. Please contact your H.C. Wainwright or Jefferies salesperson, or Lumos Pharma Investor Relations, to schedule one-on-one meetings with the management team during the conferences or thereafter.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma's lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2 clinical trial, the OraGrowthH210 Trial, a PK/PD trial, the OraGrowthH212 Trial, and a switch trial, the OraGrowthH213 Trial for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit <https://lumos-pharma.com/>.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.



Source: Lumos Pharma, Inc.